Merck & Company Inc (MRK)vsNeuphoria Therapeutics Inc (NEUP)
MRK
Merck & Company Inc
$109.18
+2.74%
HEALTHCARE · Cap: $274.03B
NEUP
Neuphoria Therapeutics Inc
$5.27
+1.54%
HEALTHCARE · Cap: $27.76M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 433691% more annual revenue ($65.01B vs $14.99M). MRK leads profitability with a 28.1% profit margin vs -37.8%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
NEUP
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+66.4%
Fair Value
$11.93
Current Price
$5.27
$6.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while NEUP is a turnaround play — different risk/reward profiles.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 33/100), backed by strong 28.1% margins. NEUP offers better value entry with a 66.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a pioneering biotechnology firm focused on developing groundbreaking therapies for mental health disorders through the use of psychedelic compounds and innovative drug delivery mechanisms. The company is dedicated to translating advanced research into effective treatments for significant unmet needs within the mental health space, thereby positioning itself as a frontrunner in the burgeoning psychedelic therapy market. With a strong pipeline of preclinical candidates, Neuphoria represents a compelling investment opportunity for institutional investors keen on engaging with emerging biotech trends poised to reshape mental health care. Its commitment to transformative therapeutic solutions underscores its potential to significantly impact the future landscape of mental health treatment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?